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Evaluation of a two-way, HIPAA-compliant text-messaging platform in a 
health system specialty pharmacy
DJ Clark, PharmD; Adam Saulles, PharmD, CSP, BCACP; Tara Berkson, PharmD, BCACP
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Disclosures
Medication Possession Ratio (MPR)Data Collection Period: February 2019 – March 2020
Study population: ≥18 years old with a diagnosis of MS 
and ≥2 dispenses of disease-modifying medications 
• Institutional Review Board-approved 
• Single-center, retrospective analysis 
• Data was collected via the electronic health record, the 
implemented text messaging application, and 
pharmacy phone system records.
• Outreach and medication refill date/time were collected 
for the 5 (or total available if <5) most recent fills 
before and after opt-in to the the text-messaging 
platform. 
• MPR was calculated based on dispense dates. 
• Results are described using simple descriptive 
statistics and T-tests, where applicable. 
Patient Enrollment Status:
Outcomes:
• Response to pharmacy caregiver outreach via text-
message was significantly faster than response to 
traditional phone-call outreach overall.
• Patients who switched enrollment from phone-call 
outreach to utilizing a text-message based platform 
experienced a significant reduction in response time to 
pharmacy outreach.
• Improved response time also translated into improved 
overall medication adherence. Patients utilizing the text-
message based platform demonstrated a significantly 
improved MPR. 
• A 21% increase in the specialty pharmacy’s patient 
management program enrollment was realized following 
7.5 months of utilization of the implemented text-
messaging platform. Enrollment in this management 
program allows for comprehensive follow-up and 
increased clinical monitoring by a specialty pharmacist. 
• Satisfaction surveys reveal that enrolled patients are 
highly satisfied with the implemented platform. 
• Pharmacy phone-call volume did not change significantly 
post-implementation of the text-messaging platform, 
although this result may be confounded by the 
consistently increasing prescription volume in the 
specialty pharmacy. Furthermore, patients with MS 
represent only ~10% of the population served by the 
specialty pharmacy. Patients with many other disease 
states continue to require phone call outreach. Future 
expansion of the text-messaging option to additional 
disease states is expected to reduce total pharmacy call 
volume in the future. 
Study Limitations:
• Only the five most recent dispenses were analyzed pre-
and post-intervention. 
• Results of satisfaction surveys may be subject to 
selection bias. Patients who are comfortable utilizing the 
text-messaging platform are more likely to respond to 
satisfaction surveys submitted through the platform itself. 
• Specialty medications represent a growing proportion of 
prescription drug expenditures in the United States. In 
2018, specialty medications represented 37.4% of 
medication spending, but accounted for only 1.9% of 
medication dispenses.1
• Increased utilization of specialty medications for 
maintenance therapy is especially apparent in the 
population of patients living with Multiple Sclerosis (MS). 
• A 2017 study demonstrated that only ~50% of patients 
with MS are adherent to prescribed regimens when 
initiating disease-modifying therapy.2
• Prior to July 2019, the health system specialty pharmacy 
only contacted MS patients via phone call to perform refill 
coordination and pharmacist follow-up. 
• In July 2019, a HIPAA-compliant messaging platform was 
implemented. With this program, patients can respond to 
refill inquiries at their convenience and provide typed 
responses to medication-related safety, adherence, and 
efficacy follow-up questions sent by specialty 
pharmacists. 
The health system specialty pharmacy has utilized a 
HIPAA-compliant text-messaging platform to successfully 
improve patient response time, treatment adherence, 
and overall engagement with clinical pharmacy services, 
while delivering a positive patient experience.
Methodology
To determine the impact of the implementation of a 
HIPAA-compliant text-messaging platform on patient 
adherence, engagement, and satisfaction 
Results
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Objectives 
Primary Outcome: Time between pharmacy technician 
outreach and medication refill
Secondary Outcomes:
• Medication possession ratio (MPR)
• Proportion of patients enrolled in the specialty 
pharmacy’s patient management program
• Patient satisfaction assessed by in-application surveys 
• Specialty pharmacy phone-call volume
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Next Steps 
These results will be pivotal in expanding use of a text-
messaging platform to patients filling medications for 
other conditions at the specialty pharmacy.
1. James, D. Specialty Drug Spending Grows While Traditional Medicine Spending Drops. Pharmacy 
Times, 2018. 
2. Munsell M, et al. An evaluation of adherence in patients with multiple sclerosis newly initiating treatment 
with a self-injectable or an oral disease-modifying drug. Patient preference and adherence, 2017
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Total Opted-Out of Texting Program Enrolled in Texting Program
Patients (N=515)
Average Age 51.8 years 
Female 403 (78%)
Medication 
Aubagio® (teriflunomide) 58 (11%)
Avonex® (interferon beta-1a) 64 (12%)
Betaseron® (interferon beta-1b) 4 (<1%)
Copaxone® (glatiramer acetate) 55 (11%)
Dalfampridine generic 12 (2%)
Gilenya® (fingolimod) 63 (12%)
Glatiramer acetate generic 60 (12%)
Glatopa® (glatiramer acetate) 3 (<1%)
Plegridy® (peginterferon beta-1a) 19 (4%)
Rebif® (interferon beta-1a) 25 (5%)
Tecfidera® (dimethyl fumarate) 153 (30%)
Enrolled in Patient 
Management Program 
Opted-Out of Patient 
Management Program 
Enrolled in Text-
Messaging Program 358 (70%) 11 (2%)
Opted-Out of Text-
Messaging Program 63 (12%) 83 (16%)
